Read by QxMD icon Read


Azmil H Abdul-Rahim, Ana-Cristina Perez, Rachael L MacIsaac, Pardeep S Jhund, Brian L Claggett, Peter E Carson, Michel Komajda, Robert S McKelvie, Michael R Zile, Karl Swedberg, Salim Yusuf, Marc A Pfeffer, Scott D Solomon, Gregory Y H Lip, Kennedy R Lees, John J V McMurray
Aims: The incidence and predictors of stroke in patients with heart failure and preserved ejection fraction (HF-PEF), but without atrial fibrillation (AF), are unknown. We described the incidence of stroke in HF-PEF patients with and without AF and predictors of stroke in those without AF. Methods and results: We pooled data from the CHARM-Preserved and I-Preserve trials. Using Cox regression, we derived a model for stroke in patients without AF in this cohort and compared its performance with a published model in heart failure patients with reduced ejection fraction (HF-REF)-predictive variables: age, body mass index, New York Heart Association class, history of stroke, and insulin-treated diabetes...
March 7, 2017: European Heart Journal
N S Luo, H F Zhang, P M Liu, Y Q Lin, T C Huang, Y Yang, J F Wang
Objective: Diagnostic efficacy of serum markers is low for heart failure patients with preserved left ventricular ejection fraction (HF-pEF) as compared to heart failure patients with reduced left ventricular ejection fraction.We sought to explore the diagnostic value of serum levels of soluble ST2 (sST2) combined with interleukin-33 (IL-33) for the diagnosis of HF-pEF in this study. Methods: A total of 376 patients with HF-pEF (HF group), 376 matched-control patients without heart failure who shared similar clinical characteristics (non-HF group) were included in the study...
March 24, 2017: Zhonghua Xin Xue Guan Bing za Zhi
Vaibhav B Patel, Judith N Lezutekong, Xueyi Chen, Gavin Y Oudit
Heart failure (HF) is a common cause of death and disability and a major economic burden in industrialized nations. Heart disease remains the leading cause of death in North America, with ischemic and hypertensive heart disease as the leading cause of HF. Various basic and clinical studies have established the role of an activated renin-angiotensin (Ang) system and Ang II generation in the progression of HF. Inhibition of an activated renin-Ang system using Ang-converting enzyme inhibitors, Ang II type 1 receptor blockers, and mineralocorticoid receptors antagonists have shown clinical benefits in patients with HF, although, largely limited to HF with reduced ejection fraction (HF-rEF)...
December 23, 2016: Canadian Journal of Cardiology
D Aras, S Aydogdu, E Bozkurt, Y Cavusoglu, M Eren, C Erol, S Gulec, F Sarioz, Z Ongen, O Ozdemir, L Tokgozoglu, E Yeter, M B Yilmaz
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Siddique A Abbasi, Ravi V Shah, Steven E McNulty, Adrian F Hernandez, Marc J Semigran, Gregory D Lewis, Michael Jerosch-Herold, Raymond J Kim, Margaret M Redfield, Raymond Y Kwong
Given the emerging recognition of left atrial structure and function as an important marker of disease in heart failure with preserved ejection fraction (HF-pEF), we investigated the association between left atrial volume and function with markers of disease severity and cardiac structure in HF-pEF. We studied 100 patients enrolled in the PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial who underwent cardiac magnetic resonance (CMR), cardiopulmonary exercise testing, and blood collection before randomization...
2016: PloS One
Ali Amr, Elham Kayvanpour, Farbod Sedaghat-Hamedani, Tiziano Passerini, Viorel Mihalef, Alan Lai, Dominik Neumann, Bogdan Georgescu, Sebastian Buss, Derliz Mereles, Edgar Zitron, Andreas E Posch, Maximilian Würstle, Tommaso Mansi, Hugo A Katus, Benjamin Meder
The search for a parameter representing left ventricular relaxation from non-invasive and invasive diagnostic tools has been extensive, since heart failure (HF) with preserved ejection fraction (HF-pEF) is a global health problem. We explore here the feasibility using patient-specific cardiac computer modeling to capture diastolic parameters in patients suffering from different degrees of systolic HF. Fifty eight patients with idiopathic dilated cardiomyopathy have undergone thorough clinical evaluation, including cardiac magnetic resonance imaging (MRI), heart catheterization, echocardiography, and cardiac biomarker assessment...
August 2016: Genomics, Proteomics & Bioinformatics
Joan Carles Trullàs, Luís Manzano, Francesc Formiga, Oscar Aramburu-Bodas, María Angustias Quesada-Simón, José Luís Arias-Jiménez, David García-Escrivá, Jorge Manuel Romero-Requena, Rosa Jordana-Comajuncosa, Manuel Montero-Pérez-Barquero
OBJECTIVE: The aim of this study was to determine whether patients with heart failure (HF) who recover left ventricular ejection fraction (LVEF), termed here as 'Rec-HF', have a distinct clinical profile and prognosis compared with patients with HF and reduced LVEF (HF-REF) or HF and preserved LVEF (HF-PEF). METHODS: We evaluated and classified patients from the Spanish Heart Failure Registry into three categories based on enrollment/follow-up echocardiograms: HF-PEF (LVEF ≥50%), HF-REF (LVEF persistently <50%) and Rec-HF (LVEF on enrollment <50% but normalized during follow-up)...
July 19, 2016: Cardiology
Agnieszka Kapłon-Cieślicka, Agata Tymińska, Michał Peller, Paweł Balsam, Krzysztof Ozierański, Michalina Galas, Michał Marchel, Maria G Crespo-Leiro, Aldo Pietro Maggioni, Jarosław Drożdż, Krzysztof J Filipiak, Grzegorz Opolski
Compared with heart failure (HF) with reduced ejection fraction (HF-REF), the diagnosis of HF with preserved EF (HF-PEF) is more challenging. The aim of the study was to assess the prevalence of HF-PEF among patients hospitalized for HF, to evaluate the pertinence of HF-PEF diagnosis and to compare HF-PEF and HF-REF patients with respect to outcomes. The analysis included 661 Polish patients hospitalized for HF, selected from the European Society of Cardiology (ESC)-HF Long-Term Registry. Patients with an EF of ≥50% were included in the HF-PEF group and patients with an EF of <50% - in the HF-REF group...
August 15, 2016: American Journal of Cardiology
Jane A Cannon, Li Shen, Pardeep S Jhund, Inder S Anand, Michel Komajda, Robert S McKelvie, Michael R Zile, Peter E Carson, John J V McMurray
BACKGROUND: The aims of this study were to describe the prevalence of QRS prolongation and abnormal QRS morphology in patients with heart failure and preserved ejection fraction (HF-PEF) and to examine the relationship between these QRS abnormalities and clinical outcomes. METHODS AND RESULTS: We categorized patients in the Irbesartan in Heart Failure with Preserved Ejection Fraction trial (I-PRESERVE) according to QRS duration <120 vs. ≥120 ms and QRS morphology: normal, left bundle branch block (LBBB), and right bundle branch block (RBBB) or other non-specific intra-ventricular conduction defect (IVCD)...
August 2016: European Journal of Heart Failure
N Ali-Tatar Chentir, Y Tir, L Ouabdesselam, M-T Chentir
OBJECTIVE: To assess the left ventricular (LV) filling pressures by Doppler Tissulaire Imaging (DTI) in the management of hypertensive patients with heart failure and preserved systolic function (HF-PEF) in our outpatient clinic. To involve the patient on the basis of their clinical, biological and echocardiography data, in identifying the risk factors that need change. PATIENTS AND METHODS: From 2004 to 2014, heart failure with preserved systolic function (HF-PEF) has been diagnosed in 200 consecutive hypertensive patients (pts) at our Algerian outpatient unit...
June 2016: Annales de Cardiologie et D'angéiologie
Nehal Hussain, Athanasios Charalampopoulos, Sheila Ramjug, Robin Condliffe, Charlie A Elliot, Laurence O'Toole, Andrew Swift, David G Kiely
The most common cause of pulmonary hypertension (PH) due to left heart disease (LHD) was previously rheumatic mitral valve disease. However, with the disappearance of rheumatic fever and an aging population, nonvalvular LHD is now the most common cause of group 2 PH in the developed world. In this review, we examine the challenge of investigating patients who have PH and heart failure with preserved ejection fraction (HF-pEF), where differentiating between pulmonary arterial hypertension (PAH) and PH-LHD can be difficult, and also discuss the entity of combined precapillary and postcapillary PH...
March 2016: Pulmonary Circulation
Akshay S Desai, Pardeep S Jhund
Although patients with heart failure and preserved ejection fraction (HF-PEF) represent nearly half of the population with chronic heart failure, few evidence-based medical therapies are available. The neutral overall results of the TOPCAT trial of spironolactone in HF-PEF leave clinicians who treat heart failure with an ongoing clinical dilemma. In this review, we outline an approach to the clinical management of the patient with HF-PEF synthesizing data from available clinical trials and expert consensus.
November 1, 2016: European Heart Journal
Y M Liu, S M Ma, L Yang, L L Xue, C D Qiao, L Wang, Y Y Liu, J G Yang
OBJECTIVE: To explore the diagnostic values of ratios of early diastolic peak transmitral velocity(E) to late velocity(A) (E/A) and E to early diastolic peak mitral annulus velocity (E/E') for heart failure patients with preserved ejection fraction (HF-PEF). METHODS: Two hundred and sixteen healthy people were divided into <50 years, 50-59 years, 60-69 years, and ≥70 years groups to clarify the impact of aging on E/A and E/E'. Two hundred and two newly diagnosed consecutive in-patients with HF-PEF and 221 age- and sex-matched non-heart-failure subjects with risk factors of HF-PEF (negative controls) were enrolled...
February 2016: Zhonghua Xin Xue Guan Bing za Zhi
N Ali-Tatar Chentir, Y Tir, L Ouabdesselem, M T Chentir
BACKGROUND: To assess the left ventricular (LV) filling pressures by Doppler Tissulaire Imaging (DTI), in the management of hypertensive patients with heart failure and preserved systolic function. METHODS: From 2004 to 2014, heart failure with preserved systolic function (HF-PEF) has been diagnosed in 200 consecutive hypertensive patients (pts) at the outpatient unit. Data were collected on comorbid conditions including diabetes and atrial fibrillation (AF). A LV ejection fraction > 40% is taken as the including criteria...
December 2015: Annales de Cardiologie et D'angéiologie
Joanne Simpson, Davide Castagno, Rob N Doughty, Katrina K Poppe, Nikki Earle, Iain Squire, Mark Richards, Bert Andersson, Justin A Ezekowitz, Michel Komajda, Mark C Petrie, Finlay A McAlister, Greg D Gamble, Gillian A Whalley, John J V McMurray
AIM: To investigate the relationship between heart rate and survival in patients with heart failure (HF) and coexisting atrial fibrillation (AF). METHODS AND RESULTS: Patients with AF included in the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) meta-analysis were the main focus of this analysis (3259 patients from 17 studies). The outcome was all-cause mortality at 3 years. Heart rate was analysed as a categorical (tertiles; T1 ≤77 b.p.m., T2 78-98 b...
November 2015: European Journal of Heart Failure
Elke Platz, Pardeep S Jhund, Ross T Campbell, John J McMurray
AIMS: Pulmonary oedema is a common and important finding in acute heart failure (AHF). We conducted a systematic review to describe the methods used to assess pulmonary oedema in recent randomized AHF trials and report its prevalence in these trials. METHODS AND RESULTS: Of 23 AHF trials published between 2002 and 2013, six were excluded because they were very small or not randomized, or missing full-length publications. Of the remaining 17 (n = 200-7141) trials, six enrolled patients with HF and reduced ejection fraction (HF-REF) and 11, patients with both HF-REF and HF with preserved ejection fraction (HF-PEF)...
September 2015: European Journal of Heart Failure
João Pedro Ferreira, Nicolas Girerd, Patrick Rossignol, Faiez Zannad
Randomized controlled trials (RCTs) are essential to develop advances in heart failure (HF). The need for increasing numbers of patients (without substantial cost increase) and generalization of results led to the disappearance of international boundaries in large RCTs. The significant geographic differences in patients' characteristics, outcomes, and, most importantly, treatment effect observed in HF trials have recently been highlighted. Whether the observed regional discrepancies in HF trials are due to trial-specific issues, patient heterogeneity, structural differences in countries, or a complex interaction between factors are the questions we propose to debate in this review...
September 2015: European Journal of Heart Failure
Athar A Badar, Ana Cristina Perez-Moreno, Nathaniel M Hawkins, Pardeep S Jhund, Alan P T Brunton, Inder S Anand, Robert S McKelvie, Michel Komajda, Michael R Zile, Peter E Carson, Roy S Gardner, Mark C Petrie, John J V McMurray
BACKGROUND: The aim of our study was to investigate the relationship between coronary artery disease (CAD), angina, and clinical outcomes in patients with heart failure and preserved ejection fraction enrolled in the irbesartan in patients with heart failure and preserved systolic function (I-Preserve) trial. METHODS AND RESULTS: The mean follow-up period for the 4128 patients enrolled in I-Preserve was 49.5 months. Patients were divided into 4 mutually exclusive groups according to history of CAD and angina: patients with no history of CAD or angina (n=2008), patients with no history of CAD but a history of angina (n=649), patients with a history of CAD but no angina (n=468), and patients with a history of CAD and angina (n=1003); patients with no known CAD or angina were the reference group...
July 2015: Circulation. Heart Failure
Søren L Kristensen, Pardeep S Jhund, Lars Køber, Robert S McKelvie, Michael R Zile, Inder S Anand, Michel Komajda, John G F Cleland, Peter E Carson, John J V McMurray
OBJECTIVES: The aim of this study was to investigate N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and recent heart failure (HF) hospitalization as predictors of future events in heart failure - preserved ejection fraction (HF-PEF). BACKGROUND: Recently, doubt has been expressed about the value of a history of HF hospitalization as a predictor of adverse cardiovascular outcomes in patients with HF and HF-PEF. METHODS: We estimated rates and adjusted hazard ratios (HRs) for the composite endpoint of cardiovascular death or HF hospitalization, according to history of recent HF hospitalization and baseline NT-proBNP level in the I-PRESERVE (Irbesartan in Heart Failure with Preserved systolic function) trial...
June 2015: JACC. Heart Failure
C Berry, K K Poppe, G D Gamble, N J Earle, J A Ezekowitz, I B Squire, J J V McMurray, F A McAlister, M Komajda, K Swedberg, A P Maggioni, A Ahmed, G A Whalley, R N Doughty, L Tarantini
BACKGROUND: Anaemia is common among patients with heart failure (HF) and is an important prognostic marker. AIM: We sought to determine the prognostic importance of anaemia in a large multinational pooled dataset of prospectively enrolled HF patients, with the specific aim to determine the prognostic role of anaemia in HF with preserved and reduced ejection fraction (HF-PEF and HF-REF, respectively). DESIGN: Individual person data meta-analysis...
June 2016: QJM: Monthly Journal of the Association of Physicians
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"